There is great geographical variation in the distribution of hepatocellular carcinoma (HCC), with the majority of all cases worldwide found in the Asia–Pacific region, where HCC is one of the leading public health problems. Since the “Toward Revision of the Asian Pacific Association for the Study of the Liver (APASL) HCC Guidelines” meeting held at the 25th annual conference of the APASL in Tokyo, the newest guidelines for the treatment of HCC published by the APASL has been discussed. This latest guidelines recommend evidence-based management of HCC and are considered suitable for universal use in the Asia–Pacific region, which has a diversity of medical environments.
|Number of pages||54|
|Publication status||Published - 2017 Jul 1|
Bibliographical noteFunding Information:
Masao Omata received fees for being a speaker, consultant, and advisory board member from Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, Otsuka, Astellas, Gilead Sciences, Chugai, Mitsubishi Tanabe, Kyorin, Merck Sharp and Dohme, Dainippon Sumitomo, Vertex Pharmaceuticals, Takeda, Merck Serono, and Zeria. Ann-Lii Cheng received consultant fees from Novartis, Merck Serono, Eisai, Merck Sharp and Dohme, ONXEO, Bayer, Bristol-Myers Squibb, and Ono Pharmaceutical. Norihiro Kokudo received research grants from Dainippon Sumitomo, Astellas, and Taiho. Masatoshi Kudo received lecture fees from Bayer, Eisai, Merck Sharp and Dohme, and Ajinomoto, research grants from Chugai, Otsuka, Takeda, Dainippon Sumitomo, Daiichi Sankyo, Merck Sharp and Dohme, Eisai, Bayer, and AbbVie, and consulting or advisory fees from Kowa, Merck Sharp and Dohme, Bristol-Myers Squibb, Bayer, Chugai, and Taiho. Jidong Jia received consultation and speaker fees from Bristol-Myers Squibb, Gilead, Merck Sharp and Dohme, Novartis, and Roche. Sadahisa Ogasawara received a consulting or advisory fee from Bayer and Eisai and honoraria from Bayer and Eisai. Jeong Min Lee, Ryosuke Tateishi, Kwang-Hyub Han, Yoghesh K. Chawla, Shuichiro Shiina, Wasim Jafri, Diana Alcantara Payawal, Takamasa Ohki, Pei-Jer Chen, Cosmas Rinaldi A. Lesmana, Laurentius A. Lesmana, Rino A. Gani, Shuntaro Obi, A. Kadir Dokmeci, and Shiv Kumar Sarin declare that they have no conflict of interest.
© 2017, The Author(s).
All Science Journal Classification (ASJC) codes